Moderna Launches Clinical Testing for mRNA Vaccine Targeting Bundibugyo Ebola Strain
Health Canada has authorized an early-stage human trial for mRNA-1469, a vaccine designed to combat the Bundibugyo ebolavirus. This development marks the first human testing phase for a strain that currently lacks any approved immunization.
Key takeaways
- Health Canada approved the first human trials for Moderna's mRNA-1469 vaccine targeting the Bundibugyo Ebola strain.
- The clinical trial is being conducted at three Canadian sites with 80 healthy adult volunteers.
- CEPI has provided $50 million to fund the development and manufacturing of this experimental mRNA-based shot.
- Moderna has committed 500,000 doses for low-income countries at access pricing if the vaccine receives final approval.
The Clinical Trial Phase
Moderna announced on Tuesday that the first group of volunteers has received mRNA-1469, an experimental vaccine developed to counter the Bundibugyo strain of Ebola. Utilizing the same messenger RNA platform used for its COVID-19 immunizations, the company is conducting this early-stage study across three sites in Canada. The trial seeks to enroll 80 healthy adult participants to evaluate the primary safety profile and the vaccine's ability to stimulate an immune response.
Background
The Bundibugyo ebolavirus has caused significant mortality, with historical data from the U.S. Centers for Disease Control and Prevention recording over 1,650 deaths. This specific strain is currently fueling an outbreak in the Democratic Republic of Congo, which has reached 3,748 confirmed cases as of August 1. According to Richard Hatchett, chief executive of the Coalition for Epidemic Preparedness Innovations (CEPI), the rate of infection in this outbreak is exceeding the speed of the 2014-2016 West Africa epidemic. Both the World Health Organization and Africa CDC have designated the situation a public health emergency.
Why It Matters
Currently, no approved vaccine exists for the Bundibugyo strain. This research is supported by a partnership with CEPI, which committed up to $50 million to finance manufacturing and early-stage testing. Under the terms of this agreement, Moderna has pledged to provide at least 500,000 doses to low- and middle-income nations at accessible pricing should the vaccine successfully navigate the regulatory approval process.
Key Facts
- The trial involves 80 healthy adults monitored for safety and immunogenicity.
- Bundibugyo ebolavirus is responsible for 1,657 confirmed deaths in the current DRC outbreak.
- CEPI is providing $50 million in funding for the development of mRNA-1469.
- This is the second-largest Ebola outbreak ever recorded.
- Moderna intends to provide 500,000 doses to developing nations if the shot is approved.
Source: The Hindu — Sci-Tech
Related stories
Congo Ebola Outbreak Death Toll Surpasses 1,700 Amid Rapid Transmission
Maharashtra Enforces One-Year Prohibition on Analogue Paneer Citing Safety Violations
Border Maternal Health Study Reveals Preeclampsia Rates Triple National Average
